<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602091</url>
  </required_header>
  <id_info>
    <org_study_id>MAJIK Registry</org_study_id>
    <nct_id>NCT04602091</nct_id>
  </id_info>
  <brief_title>Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)</brief_title>
  <acronym>MAJIK</acronym>
  <official_title>JAKINIB Study: &quot; 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Societe Francaise de Rhumatologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bordeaux PharmacoEpi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Societe Francaise de Rhumatologie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic&#xD;
      arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class&#xD;
      needs to be better defined and its use in real life further established.&#xD;
&#xD;
      The French Society of Rheumatologists intends to coordinate a prospective national registry&#xD;
      study for this follow-up.&#xD;
&#xD;
      This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with&#xD;
      psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for 5&#xD;
      years.&#xD;
&#xD;
      This registry is a longitudinal, multicentre, observational registry study. The objective of&#xD;
      this national registry is to get a better understanding of the safety profiles of JAK&#xD;
      inhibitors and get knowledge of their use in daily practice in order to optimize this use and&#xD;
      potentially integrate JAK inhibitors into personalised medicine strategies.&#xD;
&#xD;
      This registry will generate efficacy data, especially therapeutic maintenance, observation,&#xD;
      allowing inter-registry comparisons with other biologic compounds in the French population,&#xD;
      and can be aggregated with other similar registries in other countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      This registry is a longitudinal, multicentre, observational registry study, with continuous&#xD;
      and ambispective collection of clinical and laboratory data. The patients will be followed&#xD;
      for 5 years, regardless of the therapeutic modifications occurring thereafter.&#xD;
&#xD;
      Target population:&#xD;
&#xD;
      Patients initiating JAK inhibitor therapy for inflammatory rheumatic disorder.&#xD;
&#xD;
      Number of patients and centres :&#xD;
&#xD;
        -  The objective is to include, per drug available on the market, at least 300 to 500&#xD;
           patients with RA and at least 100 to 150 patients with psoriatic arthritis. If a JAK&#xD;
           inhibitor is approved in a new indication of chronic rheumatic disease by European&#xD;
           Medicines Agency (EMA), the number of patients to include for each molecule in this&#xD;
           indication will be adjusted as a function of the prevalence/epidemiology of each&#xD;
           disease. Products currently available (baricitinib and tofacitinib) will be considered&#xD;
           at the start of this registry; then every new indication for an already approved drug or&#xD;
           every new drug in the same therapeutic class starting from the date they are placed on&#xD;
           the market will be considered.&#xD;
&#xD;
        -  More than 80 centers in France (hospital-based, public and private practice) will&#xD;
           participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Therapeutic maintenance of JAK inhibitors</measure>
    <time_frame>From the beginning of the study up to Year 1</time_frame>
    <description>The therapeutic maintenance will be measured by the retention rate ie the percentage of patients remaining treated by JAK inhibitors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Real-life tolerance of JAK inhibitors</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Occurence of adverse events and action taken (temporary or final stop to JAK inhibitor treatment upon the occurrence of adverse event).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Real-life tolerance of JAK inhibitors in sub-groups</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Occurence of adverse events and action taken (temporary or final stop to JAK inhibitor treatment upon the occurrence of adverse event), in an older population or presenting with comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of JAK inhibitors</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Evaluated using clinical data (list is not exhaustive): number of swelling joints (NAG), number of tender joints (NAD), erythrocyte sedimentation rate (ESR), levels of C-reactive protein (CRP), the visual analogic scale (VAS) for disease activity evaluated by the patient and by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of JAK inhibitors efficacy (monotherapy versus combination with DMARDS)</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Evaluate the efficacy of JAK inhibitors administered as monotherapy versus combination with a conventional synthetic DMARDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of JAK inhibitors dose (full doses versus half doses)</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of JAK inhibitors in current practice</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Starting dosage, therapeutic adjustments, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Place of JAK inhibitors in real-life practice in the treatment arsenal for patients with chronic inflammatory rheumatic disorders</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Therapeutic history of the patient regarding DMARDs before starting treatment with a JAK inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: Quality of life</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Analyse the effect of JAK inhibitors on patient reported outcomes in regard to quality of life and functional impact : Health Assessment Questionnaire (HAQ) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: Acceptance</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Analyse the effect of JAK inhibitors on patient reported outcomes in regard to acceptance : treatment acceptance questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes: Compliance</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Analyse the effect of JAK inhibitors on patient reported outcomes in regard to Compliance : compliance questionnaire (Morisky-Green self-questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug interactions</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Identify new drug interactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis if data from a National Health Database (SNIIRAM): demographics</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>With and without chaining to the patients included in this cohort with the possibility of evaluating demographics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis if data from a National Health Database (SNIIRAM): medical economics</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>With and without chaining to the patients included in this cohort with the possibility of evaluating medical economics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis if data from a National Health Database (SNIIRAM): compliance</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>With and without chaining to the patients included in this cohort with the possibility of evaluating compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establishment of an open database</measure>
    <time_frame>From the beginning of the study until the end of the 5 years follow-up</time_frame>
    <description>Establish an open database which can be integrated with other national registries with a view toward future international analyses</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Inflammatory Rheumatism</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        French patients treated for chronic inflammatory rheumatic disorders according to EMA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patients older than 18&#xD;
&#xD;
          -  Patient treated with a JAK inhibitor in accordance with EMA, for chronic inflammatory&#xD;
             rheumatisms, independent of the therapeutic line&#xD;
&#xD;
          -  Subject who is a member of a social security regime&#xD;
&#xD;
          -  Free, declared, written consent signed by the subject and the investigator on the day&#xD;
             of inclusion Exclusion criteria&#xD;
&#xD;
          -  Patient who cannot understand the implications and rules of the study&#xD;
&#xD;
          -  Patient opposition to participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elise TRUCHETET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Bordeaux - Pellegrin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerôme AVOUAC</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hôpital Cochin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clément PRATI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sorelle MBOUM</last_name>
    <phone>+33 (0)158413129</phone>
    <email>majik@rhumatologie.asso.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Natella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private office</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Bologna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Franche Comte</name>
      <address>
        <city>Belfort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lohse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clément PRATI, MD</last_name>
      <phone>+33 3 81 66 82 41</phone>
      <email>cprati@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Semerano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Elise TRUCHETET, MD</last_name>
      <phone>+33 5.56.79.55.56</phone>
      <email>marie-elise.truchetet@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bourg-en-Bresse</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Roux</last_name>
    </contact>
    <investigator>
      <last_name>Marie Couret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divi Cornec</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Christine Rat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Albert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Chartres</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Damade</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Cholet</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Leske</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Tournadre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Colombes</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Grasland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Claudepierre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Dax</name>
      <address>
        <city>Dax</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Shipley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Ramon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Douai</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Juillard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD de Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregoire Cormier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Gombert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHG Jacques Monod</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Zarnitski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaele Seror</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Dernis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene-Marc Flipo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private office</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Chassaing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Houvenagel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Coury</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infirmerie protestante de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Basch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Marseille Sainte-Marguerite</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Lafforgue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis ARNIAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Mirabel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Daien</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Morlaix</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Le Henaff</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Desmurs</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Le Goff</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Nevers</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Melac-Ducamp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Roux</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Niort</name>
      <address>
        <city>Niort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Lormeau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Orleans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine Salliot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Ambroise Pare</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Padovano</last_name>
    </contact>
    <investigator>
      <last_name>Maxime Breban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Dieude</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Lieute</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Banneville</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Fautrel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremie Sellam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Chazerain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerôme AVOUAC, MD</last_name>
      <phone>+33 1 58412586</phone>
      <email>jerome.avouac@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Germain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Hugues Salmon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry Lequerré</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Reunion</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Guillot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bégin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric BANAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine Colombey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Thomas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Eric Gottenberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline Ruyssen-Witrand</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Goupille</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Troyes</name>
      <address>
        <city>Troyes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kraoua Faten</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Valence</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elodie Constant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Deprez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Vauban</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Baudens</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

